2pqt
From Proteopedia
Line 4: | Line 4: | ||
|PDB= 2pqt |SIZE=350|CAPTION= <scene name='initialview01'>2pqt</scene>, resolution 1.780Å | |PDB= 2pqt |SIZE=350|CAPTION= <scene name='initialview01'>2pqt</scene>, resolution 1.780Å | ||
|SITE= | |SITE= | ||
- | |LIGAND= <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene> | + | |LIGAND= <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=TYX:S-(2-ANILINO-2-OXOETHYL)-L-CYSTEINE'>TYX</scene>, <scene name='pdbligand=UNX:UNKNOWN+ATOM+OR+ION'>UNX</scene> |
- | |ACTIVITY= [http://en.wikipedia.org/wiki/Arylamine_N-acetyltransferase Arylamine N-acetyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.3.1.5 2.3.1.5] | + | |ACTIVITY= <span class='plainlinks'>[http://en.wikipedia.org/wiki/Arylamine_N-acetyltransferase Arylamine N-acetyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.3.1.5 2.3.1.5] </span> |
|GENE= NAT1, AAC1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens]) | |GENE= NAT1, AAC1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens]) | ||
+ | |DOMAIN= | ||
+ | |RELATEDENTRY= | ||
+ | |RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2pqt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2pqt OCA], [http://www.ebi.ac.uk/pdbsum/2pqt PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=2pqt RCSB]</span> | ||
}} | }} | ||
Line 14: | Line 17: | ||
==Overview== | ==Overview== | ||
The human arylamine N-acetyltransferases NAT1 and NAT2 play an important role in the biotransformation of a plethora of aromatic amine and hydrazine drugs. They are also able to participate in the bioactivation of several known carcinogens. Each of these enzymes is genetically variable in human populations, and polymorphisms in NAT genes have been associated with various cancers. Here we have solved the high resolution crystal structures of human NAT1 and NAT2, including NAT1 in complex with the irreversible inhibitor 2-bromoacetanilide, a NAT1 active site mutant, and NAT2 in complex with CoA, and have refined them to 1.7-, 1.8-, and 1.9-A resolution, respectively. The crystal structures reveal novel structural features unique to human NATs and provide insights into the structural basis of the substrate specificity and genetic polymorphism of these enzymes. | The human arylamine N-acetyltransferases NAT1 and NAT2 play an important role in the biotransformation of a plethora of aromatic amine and hydrazine drugs. They are also able to participate in the bioactivation of several known carcinogens. Each of these enzymes is genetically variable in human populations, and polymorphisms in NAT genes have been associated with various cancers. Here we have solved the high resolution crystal structures of human NAT1 and NAT2, including NAT1 in complex with the irreversible inhibitor 2-bromoacetanilide, a NAT1 active site mutant, and NAT2 in complex with CoA, and have refined them to 1.7-, 1.8-, and 1.9-A resolution, respectively. The crystal structures reveal novel structural features unique to human NATs and provide insights into the structural basis of the substrate specificity and genetic polymorphism of these enzymes. | ||
- | |||
- | ==Disease== | ||
- | Known disease associated with this structure: Orthostatic intolerance OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=163970 163970]] | ||
==About this Structure== | ==About this Structure== | ||
Line 38: | Line 38: | ||
[[Category: Weigelt, J.]] | [[Category: Weigelt, J.]] | ||
[[Category: Wu, H.]] | [[Category: Wu, H.]] | ||
- | [[Category: CL]] | ||
- | [[Category: UNX]] | ||
[[Category: arylamide acetylase 1]] | [[Category: arylamide acetylase 1]] | ||
[[Category: arylamine n-acetyltransferase 1]] | [[Category: arylamine n-acetyltransferase 1]] | ||
Line 48: | Line 46: | ||
[[Category: structural genomics consortium]] | [[Category: structural genomics consortium]] | ||
- | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Mar 31 04:39:29 2008'' |
Revision as of 01:39, 31 March 2008
| |||||||
, resolution 1.780Å | |||||||
---|---|---|---|---|---|---|---|
Ligands: | , , | ||||||
Gene: | NAT1, AAC1 (Homo sapiens) | ||||||
Activity: | Arylamine N-acetyltransferase, with EC number 2.3.1.5 | ||||||
Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
Coordinates: | save as pdb, mmCIF, xml |
Human N-acetyltransferase 1
Overview
The human arylamine N-acetyltransferases NAT1 and NAT2 play an important role in the biotransformation of a plethora of aromatic amine and hydrazine drugs. They are also able to participate in the bioactivation of several known carcinogens. Each of these enzymes is genetically variable in human populations, and polymorphisms in NAT genes have been associated with various cancers. Here we have solved the high resolution crystal structures of human NAT1 and NAT2, including NAT1 in complex with the irreversible inhibitor 2-bromoacetanilide, a NAT1 active site mutant, and NAT2 in complex with CoA, and have refined them to 1.7-, 1.8-, and 1.9-A resolution, respectively. The crystal structures reveal novel structural features unique to human NATs and provide insights into the structural basis of the substrate specificity and genetic polymorphism of these enzymes.
About this Structure
2PQT is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases., Wu H, Dombrovsky L, Tempel W, Martin F, Loppnau P, Goodfellow GH, Grant DM, Plotnikov AN, J Biol Chem. 2007 Oct 12;282(41):30189-97. Epub 2007 Jul 26. PMID:17656365
Page seeded by OCA on Mon Mar 31 04:39:29 2008
Categories: Arylamine N-acetyltransferase | Homo sapiens | Single protein | Arrowsmith, C H. | Bochkarev, A. | Dombrovski, L. | Edwards, A M. | Grant, D M. | Loppnau, P. | Plotnikov, A N. | SGC, Structural Genomics Consortium. | Sundstrom, M. | Tempel, W. | Weigelt, J. | Wu, H. | Arylamide acetylase 1 | Arylamine n-acetyltransferase 1 | Bromoacetanilide | Covalent | Inhibitor | Sgc | Structural genomics consortium